Cancer National .2015 .Institute. Last updated on 2015 Mar 02; Last cited on 2015 Oct, 15 : .
Aulton M,Taylor K M .2013 .Aulton's Pharmaceutics: The Design and Manufacture of Medicines. , : 790-5.
Rang HP,Maureen DM .2012 .Rang & Dale's Pharmacology. , : 673-88.
Allen TM,Cullis PR .2013 .Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev, 65 : 36-48.
Duggan ST,Keating GM .2011 .Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS‑related Kaposi's sarcoma. Drugs, 71 : 2531-58.
Berger JL,Smith A,Zorn KK,Sukumvanich P,Olawaiye AB,Kelley J .2014 .Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. Onco Targets Ther, 7 : 1409-13.
Wasle I,Gamerith G,Kocher F,Mondello P,Jaeger T,Walder A .2015 .Nonp‑egylated liposomal doxorubicin in lymphoma: Patterns of toxicity and outcome in a large observational trial. Ann Hematol, 94 : 593-601.
La‑Beck NM,Zamboni BA,Gabizon A,Schmeeda H,Amantea M,Gehrig PA .2012 .Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol, 69 : 43-50.
Boers‑Sonder en MJ ,van Herpen CM,van der Graaf WT,Desar IM,van der Logt MG,de Beer YM .2014 .Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). Cancer Chemother Pharmacol, 74 : 457-63.
Hunault‑Ber ger M,Leguay T,Thomas X,Legrand O .2011 .A randomizedstudyofpegylated liposomal doxorubicin versus continuous‑infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: The GRAALL‑SA1 study. Haematologica, 96 : 245-52.
Fiegl M,Mlineritsch B,Hubalek M,Bartsch R,Pluschnig U,Steger GG .2011 .Singlea‑gent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: Results of an Austrian observational trial. BMC Cancer, 11 : 373.
Wong AL,Seng KY,Ong EM,Wang LZ,Oscar H,Cordero MT .2014 .Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat, 144 : 143-52.
Jurczak W,Szmit S,Sobocinski M,Machaczka M,Drozd‑Sokolowska J,Joks M .2013 .Premature cardiovascular mortality in lymphoma patients treated with (R)‑CHOP regimen - A national multicenter study. Int J Cardiol, 168 : 5212-7.
Lotrionte M,Palazzoni G,Abbate A,De Marco E,Mezzaroma E,Di Persio S .2013 .Cardiotoxicity of a non‑pegylated liposomal doxorubicin‑based regimen versus an epirubicin‑based regimen for breast cancer: The LITE (Liposomal doxorubicin‑Investigational chemotherapyT‑issue Doppler imaging Evaluation) randomized pilot study. Int J Cardiol, 167 : 1055-7.
Chastagner P,Devictor B,Geoerger B,Aerts I,Leblond P,Frappaz D .2015 .Phase I study of nonp‑egylated liposomal doxorubicin in children with recurrent/refractory high‑grade glioma. Cancer Chemother Pharmacol, 76 : 425-32.
Xu L,Wang W,Sheng YC,Zheng QS .2010 .Pharmacokinetics and its relation to toxicity of pegylated‑liposomal doxorubicin in Chinese patients with breast tumours. J Clin Pharm Ther, 35 : 593-601.
Turini M,Piovesana V,Ruffo P,Ripellino C,Cataldo N. .2015 .An assessment of chemotherapy‑induced nausea and vomiting direct costs in three EU countries. Drugs Context, 4 : 212285.
Monk BJ,Herzog TJ,Kaye SB,Krasner CN,Vermorken JB,Muggia FM .2010 .Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol, 28 : 3107-14.
Crivellari D,Gray KP,Dellapasqua S,Puglisi F,Ribi K,Price KN .2013 .Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial. Breast, 22 : 1307.
Lee HY,Yang BM,Hong JM,Lee TJ,Kim BG,Kim JW .2013 .Cost‑utility analysis for platinum‑sensitive recurrent ovarian cancer therapy in South Korea: Results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model. Clinicoecon Outcomes Res, 5 : 297-307.
Staropoli N,Ciliberto D,Botta C,Fiorillo L,Gualtieri S,Salvino A .2013 .A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it. J Ovarian Res, 6 : 10.
Anders CK,Adamo B,Karginova O,Deal AM,Rawal S,Darr D .2013 .Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One, 8 : e61359.
Bosetti R,Ferrandina G,Marneffe W,Scambia G,Vereeck L .2014 .Cost‑effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: Comparing chemotherapy with nanotherapy. Nanomedicine (Lond), 9 : 21758-6.
Vici P,Colucci G,Giotta F,Sergi D,Filippelli G,Perri P .2011 .A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first‑line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res, 30 : 39.
Osoba D,Northfelt DW,Budd DW,Himmelberger D .2001 .Effect of treatment on health‑related quality of life in acquired immunodeficiency syndrome (AIDS)‑related Kaposi's sarcoma: A randomized trial of pegylated‑liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest, 19 : 573-80.
Kushnir CL,Angarita AM,Havrilesky LJ,Thompson S,Spahlinger D,Sinno AK .2015 .Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). Gynecol Oncol, 137 : 503-7.
Lal S,Mahajan A,Chen WN,Chowbay B .2010 .Pharmacogenetics of target genes across doxorubicin disposition pathway: A review. Curr Drug Metab, 11 : 115-28.
Larbi A,Rymkiewicz P,Vasudev A,Low I,Shadan NB,Mustafah S .2013 .The immune system in the elderly: A fair fight against diseases?. Aging Health, 9 : 354-7.
Ma H,Chen M,Liu J,Li Y,Li J .2015 .Serious stomatitis and esophagitis: A peculiar mucous reaction induced by pegylated liposomal doxorubicin. An Bras Dermatol, 90 3 Suppl 1 : 209-11.
Cohn DE,Shimp WS .2015 .The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum‑resistant ovarian cancer: A lowv‑alue intervention?. Gynecol Oncol Rep, 13 : 47-8.
.2005 .Cost Effectiveness and Strategic Planning (WHO‑CHOICE). [Last cited on 2015 Oct, 17 : .